Somaxon Pharmaceuticals, in partnership with BioTie, has initiated a phase II-III clinical study for treating pathological gambling and a pilot phase II study for nicotine addiction smoking cessation. This promising development reflects a focus on addressing behavioral health issues, potentially signaling a positive social and financial impact.